KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Current Liabilities (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Total Current Liabilities for 15 consecutive years, with $338.2 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 15.65% to $338.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $338.2 million through Dec 2025, up 15.65% year-over-year, with the annual reading at $338.2 million for FY2025, 15.65% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $338.2 million at Supernus Pharmaceuticals, up from $330.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $735.5 million in Q2 2022, with the low at $234.7 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $375.7 million, with a median of $292.0 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities surged 209.31% in 2022, then tumbled 65.66% in 2023.
  • Over 5 years, Total Current Liabilities stood at $315.4 million in 2021, then soared by 118.14% to $688.0 million in 2022, then crashed by 57.82% to $290.2 million in 2023, then grew by 0.76% to $292.4 million in 2024, then increased by 15.65% to $338.2 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $338.2 million, $330.6 million, and $286.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.